Jiang Liu

3.2k total citations · 1 hit paper
43 papers, 1.5k citations indexed

About

Jiang Liu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Jiang Liu has authored 43 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Jiang Liu's work include Statistical Methods in Clinical Trials (7 papers), Pharmaceutical studies and practices (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Jiang Liu is often cited by papers focused on Statistical Methods in Clinical Trials (7 papers), Pharmaceutical studies and practices (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Jiang Liu collaborates with scholars based in United States, China and Taiwan. Jiang Liu's co-authors include Richard Pazdur, Yaning Wang, Ann T. Farrell, Donna Przepiorka, Christine Garnett, Kelly J. Norsworthy, Christy S. John, Chia‐Wen Ko, Jee Eun Lee and Kirsten B. Goldberg and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Jiang Liu

37 papers receiving 1.5k citations

Hit Papers

FDA Approval Summary: (Da... 2018 2026 2020 2023 2018 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
    2018 252 citations Aviva C. Krauss, Xin Gao et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiang Liu United States 16 446 426 227 165 162 43 1.5k
Sukyung Woo United States 25 460 1.0× 1.0k 2.5× 252 1.1× 74 0.4× 100 0.6× 63 2.2k
Sihem Ait‐Oudhia United States 17 336 0.8× 389 0.9× 103 0.5× 283 1.7× 94 0.6× 40 1.1k
Dinesh P. de Alwis United States 21 900 2.0× 517 1.2× 182 0.8× 48 0.3× 118 0.7× 37 1.6k
Maria Palmisano United States 23 385 0.9× 503 1.2× 174 0.8× 105 0.6× 63 0.4× 85 1.5k
Haleh Saber United States 13 606 1.4× 624 1.5× 213 0.9× 38 0.2× 235 1.5× 20 1.6k
Stijn L.W. Koolen Netherlands 25 1.1k 2.4× 545 1.3× 195 0.9× 63 0.4× 188 1.2× 155 2.3k
Christian M. Kurbacher Germany 27 1.1k 2.5× 724 1.7× 295 1.3× 45 0.3× 98 0.6× 92 2.3k
Albert J. ten Tije Netherlands 25 1.4k 3.1× 337 0.8× 110 0.5× 56 0.3× 109 0.7× 83 2.1k
Gerald J. Fetterly United States 24 609 1.4× 901 2.1× 155 0.7× 36 0.2× 98 0.6× 88 1.9k
Boon-Cher Goh Singapore 25 978 2.2× 1.3k 3.1× 182 0.8× 55 0.3× 73 0.5× 57 2.6k

Countries citing papers authored by Jiang Liu

Since Specialization
Citations

This map shows the geographic impact of Jiang Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiang Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiang Liu more than expected).

Fields of papers citing papers by Jiang Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiang Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiang Liu. The network helps show where Jiang Liu may publish in the future.

Co-authorship network of co-authors of Jiang Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiang Liu. A scholar is included among the top collaborators of Jiang Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiang Liu. Jiang Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jiang, et al.. (2025). Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations. Journal of Translational Medicine. 23(1). 600–600. 1 indexed citations
2.
Lin, Wan‐Wan, Jiang Liu, Wenqiao Zhang, et al.. (2025). TeamLoRA: Boosting Low-Rank Adaptation with Expert Collaboration and Competition. 13622–13637.
3.
Bai, Jane P. F., Miao Zhao, Jie Wang, et al.. (2024). Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update report. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2102–2110. 7 indexed citations
4.
Zhou, Yunlong, et al.. (2024). Performance of photocatalytic water splitting for hydrogen production using kelp as a sacrificial agent. International Journal of Hydrogen Energy. 85. 683–693. 14 indexed citations
5.
Sun, Xiaofei, et al.. (2024). Femtosecond laser cutting of LiFePO4 electrodes: Kerf geometry, process optimization, and electrochemical performance. Journal of Energy Storage. 101. 113859–113859. 2 indexed citations
6.
7.
8.
Liu, Jiang, et al.. (2023). Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics & Systems Pharmacology. 13(5). 691–709. 23 indexed citations
9.
Wang, Li, Jiang Liu, Justin Earp, et al.. (2023). Model‐Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective. The Journal of Clinical Pharmacology. 63(S2). S65–S77.
10.
Jelliffe, Roger W., Jiang Liu, George L. Drusano, & Marilyn N. Martinez. (2022). Individualized Patient Care Through Model-Informed Precision Dosing: Reflections on Training Future Practitioners. The AAPS Journal. 24(6). 117–117. 1 indexed citations
11.
Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations
12.
Liu, Tao, Rosemarie Neuner, Aliza Thompson, et al.. (2022). Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus. 31(4). 424–432. 16 indexed citations
13.
Zhang, Xinyuan, Yuching Yang, Manuela Grimstein, et al.. (2021). Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations. CPT Pharmacometrics & Systems Pharmacology. 10(9). 973–982. 13 indexed citations
14.
15.
Krauss, Aviva C., Xin Gao, Liang Li, et al.. (2018). FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 25(9). 2685–2690. 252 indexed citations breakdown →
16.
Pelosof, Lorraine, Steven J. Lemery, Sandra J. Casak, et al.. (2018). Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. The Oncologist. 23(4). 496–500. 15 indexed citations
17.
Norsworthy, Kelly J., Chia‐Wen Ko, Jee Eun Lee, et al.. (2018). FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. The Oncologist. 23(9). 1103–1108. 189 indexed citations
18.
Liu, Jiang, Pravin Jadhav, Shashi Amur, et al.. (2012). Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects. Hepatology. 57(3). 897–902. 9 indexed citations
19.
Garnett, Christine, Jogarao Gobburu, Venkatesh Atul Bhattaram, et al.. (2011). Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions. Clinical Pharmacokinetics. 50(10). 627–635. 112 indexed citations
20.
Wang, Jia‐Yi, et al.. (2004). Structural changes in cerebral arteries following nitric oxide deprivation: a comparison between normotensive and hypertensive rats. Thrombosis and Haemostasis. 92(7). 162–170. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sukyung Woo Breakdown of academic impact, for papers by Sihem Ait‐Oudhia Breakdown of academic impact, for papers by Dinesh P. de Alwis Breakdown of academic impact, for papers by Maria Palmisano Breakdown of academic impact, for papers by Haleh Saber Breakdown of academic impact, for papers by Stijn L.W. Koolen Breakdown of academic impact, for papers by Christian M. Kurbacher Breakdown of academic impact, for papers by Albert J. ten Tije Breakdown of academic impact, for papers by Gerald J. Fetterly Breakdown of academic impact, for papers by Boon-Cher Goh
Rankless by CCL
2026